Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant

Abstract

The present document describes a method of inhibiting cancer tumor growth in a patient in need thereof, comprising at least a first treatment comprising steps a) and b): a) administering to the patient an immune adjuvant in combination with a therapeutic monoclonal antibody specific for a tumor associated antigen; and b) administering to the patient the immune adjuvant; and a final treatment consisting of administering to the patient the therapeutic monoclonal antibody specific for a tumor associated antigen, wherein time between step a) and step b) is a time sufficient for treatment of the patient with the immune adjuvant, and wherein time between the step b) and the final treatment is from about 10 to about 14 weeks.

1 . A method of inhibiting cancer tumor growth in a patient in need thereof, comprising:
 at least a first treatment comprising steps a) and b):   a) administering to said patient an immune adjuvant in combination with a therapeutic monoclonal antibody specific for a tumor associated antigen; and   b) administering to said patient said immune adjuvant; and   a final treatment consisting of administering to said patient said therapeutic monoclonal antibody specific for a tumor associated antigen,   
       wherein time between step a) and step b) is a time sufficient for treatment of said patient with said immune adjuvant, and 
       wherein time between said step b) and said final treatment is from about 10 to about 14 weeks. 
     
     
         2 . The method of  claim 1 , which further comprises a second treatment comprising step a) and step b), with a time sufficient for treatment of said patient with said immune adjuvant between said step b) of said first treatment and step a) of said second treatment. 
     
     
         3 . The method of  claim 1 , which further comprise a third treatment comprising step a) and step b), with a time sufficient for treatment of said patient with said immune adjuvant between said step b) of said second treatment and step a) of said third treatment. 
     
     
         4 . A method of inhibiting cancer tumor growth in a patient in need thereof, comprising:
 a first, second and third treatment comprising steps a) and b):   a) administering to said patient a therapeutic monoclonal antibody specific for an tumor associated antigen in combination with an immune adjuvant; and   b) administering to said patient said immune adjuvant; and   a final treatment consisting of administering to said patient said therapeutic monoclonal antibody specific for a tumor associated antigen,   
       wherein time between step a) and step b) is from a time sufficient for treatment of said patient with said immune adjuvant, 
       wherein time between step b) of said first treatment and step a) of said second treatment, and step b) of said second treatment and step a) of said third treatment is a time sufficient for treatment of said patient with said immune adjuvant, and 
       wherein time between said third treatment and said final treatment is from about 10 to about 14 weeks. 
     
     
         5 . The method of  claim 1 , wherein said immune adjuvant is a chemotherapeutic agent, an immunostimulatory compound, an immune homeostatic checkpoint inhibitor, or a combination thereof. 
     
     
         6 . The method of  claim 1 , wherein said therapeutic monoclonal antibody specific for a tumor associated antigen is an antibody specific to CA125. 
     
     
         7 . The method of  claim 10 , wherein said antibody specific to CA125 is mAb-B43.13 (oregovomab). 
     
     
         8 . The method of  claim 1 , wherein said chemotherapeutic agent is a platinum-based chemotherapy, taxol, doxorubicin, topotecan, a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, or combinations thereof. 
     
     
         9 . The method of  claim 12 , wherein said platinum-based chemotherapy comprises cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, and combinations thereof. 
     
     
         10 . The method of any one of  claims 1  to  9 , wherein said immunostimulatory compound is a TLR3 agonist, a TLR4 agonist, or combinations thereof. 
     
     
         11 . The method of  claim 9 , wherein said TLR3 agonist is polyIC, polyICLC (Hiltonol®). 
     
     
         12 . The method of  claim 9 , wherein said chemotherapeutic agent is a combination of carboplatin and taxol. 
     
     
         13 . The method of  claim 9 , wherein said therapeutic monoclonal antibody specific for a tumor associated antigen is mAb-B43.13 (oregovomab), and said chemotherapeutic agent is a combination of carboplatin and taxol. 
     
     
         14 . The method of  claim 9 , wherein said immune homeostatic checkpoint inhibitor is an anti-PDL-1 antibody, an anti-CTLA-4 antibody, and anti-PD-1 antibody, or combinations thereof. 
     
     
         15 . The method of  claim 14 , wherein said anti-PDL-1 antibody is selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody or combinations thereof. 
     
     
         16 . The method of  claim 14 , wherein said anti-CTLA-4 antibody is selected from the group consisting of ipilimumab or tremelimumab or combinations thereof. 
     
     
         17 . The method of  claim 14 , wherein said anti-PD-1 antibody is selected from the group consisting of Nivolumab antibody, pembrolizumab antibody, pidilizumab antibody or combinations thereof, and AMP-224. 
     
     
         18 . The method of any one of  claim 8 , wherein said a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor is selected from the group consisting of olaparib, niraparib, rucaparib, talazoparib, veliparib, CEP 9722, E7016, and BGB-290, or combinations thereof. 
     
     
         19 . The method of any one of  claims 1  to  17 , wherein said cancer is ovarian cancer.